We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage
Read MoreHide Full Article
Sanofi (SNY - Free Report) and partner Translate Bio (TBIO - Free Report) announced the initiation of a phase I/II study on their mRNA-based vaccine candidate, MRT5500.
The phase I/II clinical study on MRT5500 will assess the vaccine’s safety, immune response and reactogenicity. The study is expected to enroll 415 adult participants. Interim data from the study is expected to be presented in the third quarter. Pre-clinical data on MRT5500, announced last year, showed that two doses of MRT5500-induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients.
Sanofi stock has declined 1.2% this year so far compared with a decrease of 0.6% for the industry
Meanwhile, Sanofi is also making an adjuvanted recombinant protein-based COVID-19 vaccine candidate in partnership with Glaxo (GSK - Free Report) . The vaccine is being developed by combining Sanofi’s recombinant protein-based technology with Glaxo’s pandemic adjuvant technology.
In December, the companies had announced a delay in the development plans of the vaccine due to insufficient immune response in older adults in early-stage studies. Data from a phase I/II study showed that in adults aged 18 to 49 years, the candidate showed an immune response comparable to patients who recovered from COVID-19. However, in older adults, the candidate demonstrated a low immune response, which the companies believe may be due to an insufficient concentration of the antigen.
To address this problem, last month, they announced the start of a new phase II study on their adjuvanted vaccine candidate with an improved antigen formula.
The new phase II study aims to select the most appropriate antigen dosage for adults of all ages for phase III evaluation. If the data of the phase II study are positive, the companies plan to start a phase III study in the second quarter of 2021 and the vaccine is now expected to be available in the fourth quarter of 2021.
Incidentally, Sanofi is lagging in its COVID-19 vaccine development efforts. Pfizer/BioNTech, Moderna (MRNA - Free Report) , AstraZeneca and J&J have already launched their COVID-19 vaccines in several countries and vaccinations are in full swing.
In a separate press release, Sanofi announced positive results from a phase III study evaluating its cancer drug, Libtayo (cemiplimab) monotherapy in patients with advanced cervical cancer regardless of PD-L1 status. The Independent Data Monitoring Committee (IDMC) recommended the study be stopped early as the study data demonstrated an overall survival (OS) benefit in these patients. The data showed that patients receiving Libtayo experienced a 31% reduced risk of death (in total patient population) compared to chemotherapy. The company plans to file regulatory applications for the indication in 2021. Libtayo is approved for certain patients with advanced non-small cell lung cancer, basal cell carcinoma and advanced cutaneous squamous cell carcinoma.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
Sanofi (SNY)/Translate Bio COVID-19 Vaccine in Clinical Stage
Sanofi (SNY - Free Report) and partner Translate Bio (TBIO - Free Report) announced the initiation of a phase I/II study on their mRNA-based vaccine candidate, MRT5500.
The phase I/II clinical study on MRT5500 will assess the vaccine’s safety, immune response and reactogenicity. The study is expected to enroll 415 adult participants. Interim data from the study is expected to be presented in the third quarter. Pre-clinical data on MRT5500, announced last year, showed that two doses of MRT5500-induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients.
Sanofi stock has declined 1.2% this year so far compared with a decrease of 0.6% for the industry
Meanwhile, Sanofi is also making an adjuvanted recombinant protein-based COVID-19 vaccine candidate in partnership with Glaxo (GSK - Free Report) . The vaccine is being developed by combining Sanofi’s recombinant protein-based technology with Glaxo’s pandemic adjuvant technology.
In December, the companies had announced a delay in the development plans of the vaccine due to insufficient immune response in older adults in early-stage studies. Data from a phase I/II study showed that in adults aged 18 to 49 years, the candidate showed an immune response comparable to patients who recovered from COVID-19. However, in older adults, the candidate demonstrated a low immune response, which the companies believe may be due to an insufficient concentration of the antigen.
To address this problem, last month, they announced the start of a new phase II study on their adjuvanted vaccine candidate with an improved antigen formula.
The new phase II study aims to select the most appropriate antigen dosage for adults of all ages for phase III evaluation. If the data of the phase II study are positive, the companies plan to start a phase III study in the second quarter of 2021 and the vaccine is now expected to be available in the fourth quarter of 2021.
Incidentally, Sanofi is lagging in its COVID-19 vaccine development efforts. Pfizer/BioNTech, Moderna (MRNA - Free Report) , AstraZeneca and J&J have already launched their COVID-19 vaccines in several countries and vaccinations are in full swing.
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In a separate press release, Sanofi announced positive results from a phase III study evaluating its cancer drug, Libtayo (cemiplimab) monotherapy in patients with advanced cervical cancer regardless of PD-L1 status. The Independent Data Monitoring Committee (IDMC) recommended the study be stopped early as the study data demonstrated an overall survival (OS) benefit in these patients. The data showed that patients receiving Libtayo experienced a 31% reduced risk of death (in total patient population) compared to chemotherapy. The company plans to file regulatory applications for the indication in 2021. Libtayo is approved for certain patients with advanced non-small cell lung cancer, basal cell carcinoma and advanced cutaneous squamous cell carcinoma.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>